At the forefront of the intersection between artificial intelligence and biopharmaceuticals, domestic large models are accelerating from "general conversation" to "specialized expertise."

Recently, the Institute for Intelligent Manufacturing at Tsinghua University (AIR) jointly with Shuimu Molecular officially open-sourced a general foundation model for chemical molecules named BioMedGPT-Mol. This action marks a significant step forward in the efforts of research institutions and innovative enterprises to promote the intelligence and standardization of drug development.

As a "large language model" specifically designed for chemical molecule design, BioMedGPT-Mol is characterized by its universal representation capability. Unlike traditional fragmented AI algorithms, it can understand complex molecular structures, chemical bonds, and physicochemical properties just as humans understand language, demonstrating strong generalization ability in multiple downstream tasks such as drug screening, property prediction, and molecular generation.

Institute for Intelligent Manufacturing at Tsinghua University (AIR) has been committed to using AI technology to solve industrial pain points, while Shuimu Molecular has deep technical experience in the field of biopharmaceutical large models. Their decision to open-source this model aims to provide global researchers with a high-quality foundational platform, lower the barriers to AI applications in the chemical field, and shorten the long drug development cycle.

With the addition of BioMedGPT-Mol, the digitalization process of chemistry and life sciences is entering a new paradigm of "pre-training + fine-tuning." When the mysteries of molecules can be more accurately deconstructed in digital language, humanity is one step closer to efficient and low-cost precision medicine.